Abivax (ABVX) Stock Forecast & Price Target

Q: What analysts cover Abivax?

Abivax has been rated by research analysts at Barclays , BTIG Research , Citizens Jmp , Guggenheim , HC Wainwright , Jefferies Financial Group , Leerink Partners , Morgan Stanley , Piper Sandler , The Goldman Sachs Group , Truist Financial , Wedbush , and Weiss Ratings in the past 90 days.

$91.06 -3.81 (-4.02%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$91.94 +0.88 (+0.96%)

As of 09/25/2026 07:51 PM Eastern

Compare

Abivax - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
1

Hold
1

Buy
14

Based on 16 Wall Street analysts who have issued ratings for Abivax in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 1 has given a sell rating, 1 has given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for ABVX.

Consensus Price Target

$156.69
72.08% Upside

According to the 16 analysts' twelve-month price targets for Abivax, the average price target is $156.69. The highest price target for ABVX is $187.00, while the lowest price target for ABVX is $118.00. The average price target represents a forecasted upside of 72.08% from the current price of $91.06.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ABVX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Abivax and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABVX Analyst Ratings Over Time

Type	Current Forecast 9/27/25 to 9/27/26	1 Month Ago 8/28/25 to 8/28/26	3 Months Ago 6/29/25 to 6/29/26	1 Year Ago 9/27/24 to 9/27/25
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	13 Buy rating(s)	12 Buy rating(s)	8 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$156.69	$156.50	$130.08	$102.14
Forecasted Upside	72.08% Upside	38.07% Upside	35.29% Upside	23.30% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ABVX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABVX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Abivax Stock vs. The Competition

Type	Abivax	Healthcare Companies	Broader Market
Consensus Rating Score	2.88	2.31	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	72.08% Upside	764.10% Upside	19.20% Upside
News Sentiment Rating	Neutral News See Recent ABVX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/22/2026	Truist Financial 3 of 5 stars	Gregory Renza Not Rated	Lower Target	Buy	$155.00 ➝ $151.00	+46.98%
9/22/2026	Wedbush 5 of 5 stars	David Nierengarten 5 of 5 stars	Lower Target	Neutral	$140.00 ➝ $118.00	+14.06%
9/22/2026	Barclays 3 of 5 stars	Etzer Darout 5 of 5 stars	Reiterated Rating	Overweight	$148.00	+43.06%
9/9/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rajan Sharma Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$155.00	+29.75%
7/24/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Judah Frommer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$180.00	+39.28%
7/17/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D-)
7/9/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Allison Bratzel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$165.00 ➝ $175.00	+26.32%
7/1/2026	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Butler Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Outperform	$187.00	+37.51%
6/30/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
6/30/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
25 candidates screened. 5 made it. (Ad) More than 25 candidates were screened for share price between $1 and $5, market cap above $100 million, daily volume over 500,000 shares, and over $10 million in trailing revenue. Only five stocks cleared every filter, spanning five different sectors. Two are profitable today, and one pays a substantial dividend. The report also flags what could go wrong with each pick, including dilution and convertible debt. See the five stocks that survived this strict revenue screen
6/30/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Julian Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$150.00 ➝ $175.00	+82.01%
6/30/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Faisal Khurshid Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$108.00 ➝ $158.00	+18.53%
6/30/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thomas Smith Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$140.00 ➝ $148.00	+11.52%
6/3/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$136.00	+52.99%
6/2/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
4/9/2026	Oddo Bhf Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
1/8/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$131.00	+3.57%
7/23/2025	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sam Slutsky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$45.00 ➝ $101.00	+49.26%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 09:54 AM ET.

ABVX Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Abivax is $156.69, with a high forecast of $187.00 and a low forecast of $118.00.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abivax in the last year. There is currently 1 sell rating, 1 hold rating, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABVX shares.

According to analysts, Abivax's stock has a predicted upside of 72.08% based on their 12-month stock forecasts.

Over the previous 90 days, Abivax's stock had 2 upgrades by analysts.

Abivax has been rated by research analysts at Barclays, BTIG Research, Citizens Jmp, Guggenheim, HC Wainwright, Jefferies Financial Group, Leerink Partners, Morgan Stanley, Piper Sandler, The Goldman Sachs Group, Truist Financial, Wedbush, and Weiss Ratings in the past 90 days.

Analysts like Abivax more than other "healthcare" companies. The consensus rating for Abivax is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ABVX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Abivax Recommendations

MarketBeat monitors more than a dozen sources for Abivax analyst ratings, with the most recent rating issued on 9/22/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abivax (ABVX) Stock Forecast & Price Target